In a little-noticed move, the U.S. Fish and Wildlife Service recently began denying company requests to import certain monkeys from Cambodia for use in early-stage drug research. Now, the pharmaceutical industry is trying to push back by lobbying Congress.
The National Association for Biomedical Research argues the situation is a “crisis,” with 60% of the supply of non-human primates “critical” to early-stage research now out of reach. So the trade group, which advocates for using animals in pharmaceutical research, is organizing a letter-writing campaign to urge members of Congress to “quickly secure the U.S. supply chain” without interruption.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
